These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27135195)

  • 21. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.
    Zorad S; Dou JT; Benicky J; Hutanu D; Tybitanclova K; Zhou J; Saavedra JM
    Eur J Pharmacol; 2006 Dec; 552(1-3):112-22. PubMed ID: 17064684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tight binding of the angiotensin AT(1) receptor antagonist.
    Fierensa FL; Vanderheyden PM; Roggeman C; De Backer J; Thekkumkara TJ; Vauquelin G
    Biochem Pharmacol; 2001 May; 61(10):1227-35. PubMed ID: 11322926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations.
    Fierens FL; Vanderheyden PM; Roggeman C; Vande Gucht P; De Backer JP; Vauquelin G
    Biochem Pharmacol; 2002 Apr; 63(7):1273-9. PubMed ID: 11960603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
    Inada Y
    Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
    Sidorenko BA; Preobrazhenskiĭ DV; Soplevenko AV; Ivanova NA; Stetsenko TM
    Kardiologiia; 2004; 44(1):55-65. PubMed ID: 15029149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
    Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.
    Kiriakidi S; Chatzigiannis C; Papaemmanouil C; Tzakos AG; Mavromoustakos T
    Biochim Biophys Acta Biomembr; 2020 Mar; 1862(3):183142. PubMed ID: 31830465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
    Belz GG; Butzer R; Kober S; Mutschler E
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients.
    Jung EH; Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Choi CI; Jang CG; Lee SY
    Arch Pharm Res; 2021 Dec; 44(12):1109-1119. PubMed ID: 34817825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.
    Szczuka A; Wennerberg M; Packeu A; Vauquelin G
    Br J Pharmacol; 2009 Sep; 158(1):183-94. PubMed ID: 19594756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
    Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
    Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
    Brunner HR
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K; Naka T; Chatani F; Yoshimura Y
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
    Csajka C; Buclin T; Brunner HR; Biollaz J
    Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.
    Kumar Puttrevu S; Ramakrishna R; Bhateria M; Jain M; Hanif K; Bhatta RS
    Naunyn Schmiedebergs Arch Pharmacol; 2017 May; 390(5):457-470. PubMed ID: 28190245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.